dual glp-1/gip receptor agonists and Triple Gut Peptide on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports The Effects of Dual GLP-1/GIP

7.4 Multi-modal learning health systems: embedding evidence updates into clinical workflow Over longer time scales, the application of GLP-1RAs in PCOS lies at the intersection of metabolic intervention and reproductive management

If you are switching between weekly medications, you should not administer two medications in the same week

Lundgren JR et al

Falkentoft, A

Research shows that green tea extract reduces low-density lipoproteins (LDL) in overweight and obese women after six weeks of treatment

Restraints High treatment costs and Limited reimbursements The escalating costs of anti-obesity medications, coupled with limited insurance reimbursements, present significant barriers to access for many patients